Welcome to our dedicated page for BIORA THERAPEUTICS SEC filings (Ticker: BIOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biora Therapeutics’ SEC reports aren’t just financial statements—they’re packed with clinical data on NaviCap’s colon-targeted trials and BioJet’s needle-free systemic delivery studies. Parsing dosage-release charts or R&D expense notes across multiple exhibits can take hours. That’s why investors searching for “Biora Therapeutics SEC filings explained simply” or “how to read BIOR’s proxy statement executive compensation” often feel overwhelmed.
Stock Titan’s AI solves this by digesting every 8-K material event, annual report 10-K, and quarterly earnings report 10-Q filing the moment it hits EDGAR. Our algorithms surface the data points that matter—trial endpoints, partnership revenue, and cash-runway details—then link them directly to the source paragraph. Real-time alerts flag “Biora Therapeutics Form 4 insider transactions real-time,” so you can monitor “Biora Therapeutics executive stock transactions Form 4” before the market reacts. Prefer a deep dive? Click once to see a side-by-side “Biora Therapeutics earnings report filing analysis” with peer benchmarks.
Whether you’re tracking dilution risk, assessing pipeline timelines, or comparing compensation packages, you’ll find every filing type in one place: 10-K, 10-Q, S-3, 424B, and 8-K material events explained. Need answers fast? Ask natural questions like “understanding Biora Therapeutics SEC documents with AI” or “Biora Therapeutics insider trading Form 4 transactions” and jump straight to our AI-powered summaries. From “Biora Therapeutics annual report 10-K simplified” insights to “Biora Therapeutics proxy statement executive compensation” details, Stock Titan turns complex biotech disclosures into actionable clarity.
Biora Therapeutics, Inc. (BIOR) – Schedule 13G/A Amendment No. 1
Context Capital Management, LLC, together with four related reporting persons (Michael S. Rosen, William D. Fertig, Charles E. Carnegie and Context Partners Master Fund, L.P.), has filed an amended Schedule 13G reporting beneficial ownership of 22,025 BIOR common shares as of 30 June 2025. The filing cites an outstanding share count of 4,522,702 (as of 6 Nov 2024), placing the group’s holding at 0.5 % of the company’s common equity.
- Sole voting/dispositive power: 0 shares
- Shared voting/dispositive power: 22,025 shares
- Filing basis: Passive ownership; certifications state the position was acquired in the ordinary course and not for the purpose of influencing control.
- Reporting structure: LLC is general partner and investment adviser to the Cayman-domiciled master fund; the three individuals are control persons of the LLC. All parties disclaim membership in a group and beneficial ownership except for pecuniary interest.
- Ownership status: Item 5 confirms ownership of <5 % of the class; therefore the position is below the threshold that typically triggers Schedule 13D obligations.
The amendment does not disclose purchase dates, cost basis, or any intention to alter the company’s strategy. Given the <0.5 % stake, the filing is primarily informative and is unlikely to be a market-moving catalyst on its own.
FAQ
What is the current stock price of BIORA THERAPEUTICS (BIOR)?
What is the market cap of BIORA THERAPEUTICS (BIOR)?
What is Biora Therapeutics' core business?
What are the NaviCap and BioJet platforms?
How does Biora's technology improve drug delivery?
Who are the potential beneficiaries of Biora's innovations?
How does Biora Therapeutics generate value?
What role does clinical research play in Biora's development?
How does Biora differentiate itself from other biotech companies?
What are the key areas of focus for Biora?
